跳到正文
原文
MedPage Today·· 10 天前精选AI 评分85

新型ADC药物sac-TMT在复发性或晚期子宫内膜癌中显著改善生存期

Novel ADC Boosts Survival in Pretreated Endometrial Cancer

AI 导读

TroFuse-005 试验显示,新型 ADC 药物 sac-TMT 在复发性或晚期子宫内膜癌患者中显著改善了无进展生存期(PFS)和总生存期(OS),且毒性可控,不影响生活质量。

推荐理由

TroFuse-005 试验显示新型 ADC 药物 sac-TMT 显著改善了复发性或晚期子宫内膜癌患者的无进展生存期和总生存期,有望成为新标准治疗。

正文

— Sac-TMT is currently under review at the FDA for a post-platinum/immunotherapy indication

by Gregory Laub, Senior Director, Video, MedPage Today

November 10, 2026 • 2 min read

Results from the TroFuse-005 trial presented at the annual European Society for Medical Oncology congress showed that the investigational antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival (PFS) and overall survival compared with physician's choice of chemotherapy in patients with advanced or recurrent endometrial cancer who had previously been treated with platinum-based chemotherapy and immunotherapy.

In this exclusive MedPage Today video, investigator Domenica Lorusso, MD, PhD, of Humanitas University in Italy, discusses the phase III findings, which are currently under review with the FDA.

Following is a transcript of her remarks:

In TroFuse-005, we did compare sac-TMT versus treatment of physician's choice (between doxorubicin or weekly paclitaxel) in advanced or recurrent endometrial cancer patients [previously] exposed to platinum [chemotherapy] and an immune checkpoint inhibitor, given separately or in combination. The trial had a dual primary endpoint, [PFS] and overall survival -- [PFS] evaluated by blinded independent central review -- and secondary endpoints were overall response rate, duration of response, and quality of life.

The trial met both the primary endpoints. A statistically significant and clinically relevant 41% reduction in the risk of progression was reported in patients treated with sac-TMT, with a median PFS increasing from 3.9 to 7.2 months.

But also a statistically significant and clinically relevant reduction in the risk of death was reported in patients treated with sac-TMT -- the hazard ratio was 0.68, so a 32% reduction in the risk of death, with a median overall survival increasing from 12 to 19 months.

And a significant increase in overall response rate was reported, with overall response rate doubling in patients treated with sac-TMT -- overall response rate was 17% versus 35% -- with a median duration of response of 6.9 months in the standard arm versus 11.1 months in the experimental arm.

This is the most important aspect. This did not impact the quality of life of the patient. From baseline to the pre-specified week 12, there was no difference between quality-of-life scores [between] treatment groups.

So, for all these reasons -- increased [survival] advantage, manageable toxicity profile, no impact in quality of life -- we really believe that this drug should be considered the new standard of care in this population and the new control arm in the next generation of clinical trials.

来源:MedPage Today · medpagetoday.com